SCHEMBL5548016

SCHEMBL5548016

[CH2]c1ccccc1Oc1ccccc1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
MAPK1 P28482 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
HTR7 P34969 1/20 0.37
TTR P02766 1/20 0.36
LMNA P02545 2/20 0.36
LCK P06239 1/20 0.35
TSHR P16473 1/20 0.33
RAB9A P51151 3/20 0.33
GRM4 Q14833 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 3/20 0.32
KDM4E B2RXH2 2/20 0.32
MEN1 O00255 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
NPC1 O15118 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7634253 0.85 CA1 (0.38) ALDH1A1MAPK1L3MBTL1TDP1LMNA
SCHEMBL727333 0.85 ALDH1A1 (0.48) ALDH1A1MAPK1L3MBTL1TDP1HTR7
SCHEMBL3842507 0.83 MAPK1 (0.46) ALDH1A1MAPK1L3MBTL1TDP1HTR7
SCHEMBL30274289 0.74 MAPK1 (0.39) ALDH1A1MAPK1L3MBTL1TDP1HTR7
SCHEMBL10990594 0.74 SLC6A4 (0.50) ALDH1A1MAPK1L3MBTL1TDP1LMNA
SCHEMBL74839 0.73 ALDH1A1 (0.52) ALDH1A1MAPK1L3MBTL1HTR7LMNA
SCHEMBL6900852 0.73 CA1 (0.59) ALDH1A1MAPK1L3MBTL1TDP1HTR7
SCHEMBL2848211 0.73 ALDH1A1 (0.54) ALDH1A1MAPK1L3MBTL1TDP1HTR7
SCHEMBL5541601 0.73 HPGD (0.48) ALDH1A1L3MBTL1LMNATSHRSMN1; SMN2
SCHEMBL5541162 0.73 HTR1A (0.46) ALDH1A1L3MBTL1TDP1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-4414210-A 2-Hydroxyarylethyltriazole fungicides ROHM AND HAAS COMPANY (US) 1983-11-08 US disclosed
US-4413003-A FUNGICIDES ROHM AND HAAS COMPANY (US) 1983-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885MAPK1 1392/4885L3MBTL1 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.